NCT06403761

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

Effect of CagriSema, Semaglutide and Cagrilintide on Insulin Sensitivity and Pancreatic Endocrine Function in Adults With Type 2 Diabetes

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 158 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D). CagriSema is a new investigational medicine that combines two medicines called cagrilintide and semaglutide. Doctors may not yet prescribe CagriSema. Participants will either get CagriSema, semaglutide, cagrilintide, or a ''dummy'' medicine. Which treatment the participants will get is decided by chance. Participants will get the study medicine together with the current daily diabetes medicine metformin. Participants should not take other medicines for diabetes during the study. The study will last for about 42 weeks.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Semaglutide	Participants will receive once-weekly semaglutide subcutaneously.
DRUG	Cagrilintide	Participants will receive once-weekly cagrilintide subcutaneously.
DRUG	Placebo semaglutide	Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
DRUG	Placebo cagrilintide	Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.

Timeline

• Start date: 2024-05-06
• Primary completion: 2025-12-28
• Completion: 2026-02-02
• First posted: 2024-05-08
• Last updated: 2026-02-27

Locations

1 site across 1 country: Germany